Introduction {#Sec1}
============

Surgical site infection (SSI) is one of the most common healthcare-associated infections in the acute care setting \[[@CR1]\]. The incidence of SSI varies sociogeographically and by patient-related factors, such as co-morbidities and surgery-related factors, including type of surgery \[[@CR1], [@CR2]\].

Surgical antimicrobial prophylaxis (SAP) is one of the most important modifiable factors for reducing SSI incidence. Administering SAP within 120 min before surgery decreased the risk of SSI, and the rate of SSI increased with each hour after the incision until SAP was administered \[[@CR3]\]. Guidelines for preventing SSI were published by the World Health Organization (WHO) in 2016 and by the Centers for Disease Control and Prevention (CDC) in 2017 \[[@CR1], [@CR4]\]. Although these guidelines recommend preoperative SAP within one hour of surgical incision, the optimal timing of SAP during this period (e.g., 0--30 min versus 30--60 min before incision) remains unclear.

In Japan, a number of studies on the incidence of SSI and risk factors associated with SSI in selected surgical procedures were done using a Japanese national database \[[@CR5], [@CR6]\]. The cumulative incidence of SSI in gastric and colorectal surgery ranged from 8.8 to 17.8% \[[@CR5], [@CR6]\]. Moreover, cases without complete preoperative SAP prior to the first incision in laparoscopic surgery were occasionally observed at the study institution. The infection control team at the study institution administered preoperative SAP earlier to ensure adequate time between the completion of SAP and the first skin incision as a part of a standard quality improvement initiative. The aim of this study was to evaluate the impact of changing the timing of preoperative SAP on SSI incidence in laparoscopic surgery.

Methods {#Sec2}
=======

Study design and setting {#Sec3}
------------------------

This before-after study was conducted from August 2014 to June 2017 at Tokyo Metropolitan Tama Medical Center, a 790-bed tertiary care center in Tokyo. Approximately 7000 patients annually undergo surgery at the study institution. The patients' informed consent was obtained before surgery. The institutional review board at Tokyo Metropolitan Tama Medical Center approved this study.

Participants {#Sec4}
------------

Patients over age 16 years who underwent any form of laparoscopic surgery including cholecystectomies, colectomies, gastrectomies, appendectomies, and proctectomies at the study institution were included for analysis. Patients who underwent laparoscopic surgery without follow-up information 30 days after the procedure were excluded.

Intervention {#Sec5}
------------

During the pre-intervention period (August 2014 -- June 2016), the timing of preoperative SAP differed for each operation. In July 2016, the practice of administering SAP immediately after patients enter the operating room was implemented. Once patients were transferred into the operating room, intravenous SAP was immediately administered by anesthesiologists. If vancomycin or fluoroquinolone was used for SAP, administration of the agent was begun in the hospital ward before the patient was transferred to the operating room because both of these agents require a longer period of administration. Besides the intervention noted above, there were no concurrent changes in perioperative management, including the type and dosage of antimicrobials for SAP during the study period. The recommended SAP at the study institution is described in [Appendix 1](#Sec11){ref-type="sec"}.

Data collection {#Sec6}
---------------

Clinical data were extracted from the electronic medical records. We also determined the type of laparoscopic surgery done, time of administration and completion of preoperative SAP, the American Society of Anesthesiologists (ASA) score, wound class, demographic characteristics, and underlying illnesses. Because SAP was administered intravenously over 15--30 min, we collected the data on the time of SAP completion and surgical incision. The primary outcome was the incidence of SSI as defined by the CDC criteria \[[@CR7], [@CR8]\]. Nurses and physicians in the department of infection control determined whether SSI developed in the study subjects. Patients who were discharged within the follow-up period were observed at follow-up visits as outpatients. The primary interest of this study was to examine if changing the timing of preoperative SAP affected the incidence of SSI.

Statistical analysis {#Sec7}
--------------------

We compared the incidence of SSI between the pre-intervention and intervention periods using the chi-square test. We also compared other, selected factors between the study periods. The changes in SSI incidence due to the intervention were also evaluated by segmented regression analysis of interrupted time series (ITS) data. For the sensitivity analysis, factors associated with SSI in the study period were also investigated. The usual time point of SAP (i.e., 31--60 min prior to surgical incision as a reference, in comparison with 0--30 min and \> 60 min) was used as a variable in the final model. Categorical variables were compared using Fisher's exact test or the chi-square test as appropriate. Continuous variables were compared using the Mann-Whitney *U* test. All the analyses were performed using Stata version 15 (StataCorp, College Station, TX, USA) and SPSS version 21 (IBM, Armonk, NY, USA).

Results {#Sec8}
=======

Of the 1415 patients who underwent laparoscopic surgery during the study period, 1397 patients met the inclusion criteria (Fig. [1](#Fig1){ref-type="fig"}). Table [1](#Tab1){ref-type="table"} shows a summary of the patients' baseline characteristics. In the intervention group, the median age was higher (68 years old vs. 66 years old; *p* = 0.04), and the proportion of selected comorbidities, such as cardiovascular diseases, was greater (7% vs. 3.9%; *p* = 0.01). Table [2](#Tab2){ref-type="table"} shows the changes in outcomes after implementing the intervention. The median interval between the time of completion of preoperative SAP and the time of surgical incision changed from 8 min to 26 min (*p* \<  0.001), and the number of cases without a complete preoperative SAP prior to surgical incision decreased (16.8% vs. 1.8%; *p* \<  0.001). However, the incidence of SSI did not significantly change between the pre-intervention and the intervention groups (13.8% vs. 13.2%; *p* = 0.80). The ITS model shown in Fig. [2](#Fig2){ref-type="fig"} also revealed no statistically significant changes in SSI incidence after the intervention (intercept: *P* = 0.86; trend: *P* = 0.83). The model of factors associated with SSI development and the result of sensitivity analysis is shown in [Appendix 2](#Sec11){ref-type="sec"} (univariate analysis) and Table [3](#Tab3){ref-type="table"} (multivariate analysis), respectively. Overall, a trend towards older age and longer duration of surgery was observed in patients with SSI compared with those without SSI. The results of subgroup analysis for surgery type and SSI type are shown in [Appendix 3](#Sec11){ref-type="sec"}. For all types of surgery, the number of cases without complete preoperative SAP prior to surgical incision decreased.Fig. 1Description of the study populationTable 1Baseline characteristics of patients who underwent laparoscopic surgery in the study period (*n* = 1397)Pre-intervention\
(*n* = 942)Intervention\
(*n* = 455)*P* valueAge, median, (IQR) years66 (52--75)68 (55--76)0.04Male gender, n (%)431 (56.4)260 (57.1)0.79Co-morbidities, n (%) Diabetes mellitus129 (13.7)63 (13.8)0.94 Chronic lung diseases42 (4.5)27 (5.9)0.23 Cardiovascular diseases37 (3.9)32 (7.0)0.01 Hypertension333 (35.4)180 (39.6)0.14 Dyslipidemia158 (16.8)73 (16.0)0.76Current smoker, n (%)446 (47.4)224 (49.2)0.51ASA score, n (%) 1 no disturbance207 (22.0)72 (15.8)Ref. 2 mild disturbance654 (69.4)344 (75.6)0.01 3 severe disturbance79 (8.4)37 (8.1)0.22 4 life-threatening2 (0.2)2 (0.4)0.30Wound class, n (%) 2 clean-contaminated936 (99.4)454 (99.8)0.44 3 contaminated6 (0.6)1 (0.2)0.44Emergent operation, n (%)152 (16.1)70 (15.4)0.72Type of surgery, n (%) Gastrectomy242 (25.7)129 (28.4)0.29 Cholecystectomy213 (22.6)94 (20.7)0.41 Appendectomy125 (13.3)32 (7.0)0.001 Colectomy130 (13.8)70 (15.4)0.43 Proctectomy231 (24.5)130 (28.6)0.11 Cholecystectomy and appendectomy1 (0.1)0 (0)N/AOperation time, median, (IQR) min213 (133--286)222 (145--322)0.003Abbreviations: *IQR* interquartile range, *ASA* American Society of Anesthesiologists, *N/A* not applicableTable 2Changes in outcomes after the intervention of SAPPre-intervention\
(*n* = 942)Intervention\
(*n* = 455)*P* valueSAP, n (%)940 (99.8)455 (100)SAP drip infusion time, median, (IQR) min16 (13--20)23 (17--30)\<  0.001Time from SAP completion to surgical incision, median, (IQR) min8 (2--16)26 (15--35)\<  0.001Time windows, n (%)  \> 120 min13 (1.4)3 (0.7)0.18 61--120 min11 (1.2)5 (1.1)0.57 31--60 min56 (5.9)161 (35.4)\<  0.001 0--30 min702 (74.5)278 (61.1)\<  0.001 \<  0 min158 (16.8)8 (1.8)\<  0.001SSI, n (%)130 (13.8)60 (13.2)0.80Type of SSI, n (%) Superficial SSI78 (8.3)35 (7.7)0.71 Deep SSI0 (0)4 (0.9)N/A Organ-space SSI52 (5.5)21 (4.6)0.48Abbreviations: *SAP* surgical antimicrobial prophylaxis, *IQR* interquartile range, *SSI* surgical site infection, *N/A* not applicableFig. 2Interrupted time series analysis for assessing the impact of surgical antimicrobial prophylaxis intervention on the incidence of surgical site infectionTable 3Univariate and multivariate analyses for potential risk factors for SSIUnivariate analyses, OR (95% CI)*P* valueMultivariate analyses, OR (95% CI)*P* valueAge ≥ 651.44 (1.05--1.98)0.02Male gender0.82 (0.60--1.12)0.21Diabetes mellitus0.90 (0.59--1.40)0.65Current smoker1.61 (1.12--2.20)0.0031.66 (1.14--2.40)0.01ASA score ≥ 21.44 (0.95--2.19)0.09Wound class 3 contaminated2.57 (0.50--13.36)0.26Emergent surgery0.63 (0.39--1.01)0.06Operation time ≥ 180 min2.58 (1.79--3.71)\< 0.0012.35 (1.56--3.54)\< 0.001Time windows, 31--60 minRef.Ref.  \<  0 min0.67 (0.38--1.17)0.160.78 (0.41--1.46)0.43 0--30 min0.58 (0.39--0.85)0.010.65 (0.41--1.00)0.052  \> 60 min0.72 (0.26--1.97)0.521.14 (0.38--3.42)0.81Intervention status, "yes"0.96 (0.69--1.33)0.800.79 (0.54--1.15)0.22Abbreviations: *SSI* surgical site infection, *ASA* American Society of Anesthesiologists, *OR* odds ratio, *CI* confidence interval

Discussion {#Sec9}
==========

In this study, we were able to prolong the interval between the completion of preoperative SAP and the first incision in laparoscopic surgery and to decrease the number of cases without complete preoperative SAP prior to surgical incision. The intervention successfully improved the quality of perioperative care in terms of SAP and likely increased awareness of the importance of SAP among health care workers. However, the intervention did not lead to a decrease in SSI incidence.

A number of studies have examined the optimal timing of preoperative SAP, with some studies showing that administration within 30 min prior to incision decreased the risk of postoperative infection \[[@CR9], [@CR10]\]. Other studies have reported that administration 30 to 60 min prior to incision was most effective in preventing SSI \[[@CR11]\]. A recent systematic review demonstrated that the risk of SSI increased when preoperative SAP was administered 120 min before or after the first incision \[[@CR12]\] while the WHO recommended that administration should be closer to the incision time (\< 60 min) for antimicrobials with a short half-life, such as cephalosporins and penicillins \[[@CR1]\]. At the moment, there are insufficient data to establish a more precise window \[[@CR2], [@CR13]\], and the present study was also unable to demonstrate the optimal timing for preoperative SAP.

A few previous studies showed that the risk of SSI increased when SAP was administered after incision \[[@CR5], [@CR12]\]. However, in the current study SSI incidence did not improve in the intervention period despite a decrease in the number of cases without a complete preoperative SAP prior surgical incision. Although the reasons for this result are unclear, several factors may have played a role. For instance, patients' age in the intervention period was slightly higher than in the pre-intervention period. Previous studies showed an association between aging and increased risk of SSI \[[@CR2], [@CR14], [@CR15]\]. Japan is one of the countries with an aging demographic \[[@CR16]\]. Moreover, as seen in Table [2](#Tab2){ref-type="table"}, the median duration of surgery in the intervention period was longer than in the pre-intervention period, an important risk factor for developing SSI \[[@CR17]\]. Prolonged operative time in the intervention period might be explained by the patients' age, which in turn was associated with a higher rate of comorbidities such as cardiovascular disease and a higher ASA score. Although SAP is one of the most important modifiable factors for reducing SSI, other, unmodifiable factors, including patient factors, might significantly contribute to the development SSI.

There are some limitations to our study. It is unclear whether the results would last beyond the brief, post-intervention period. Although patients' baseline characteristics in both study periods were compared, the number of collected variables was limited, and potentially predisposing factors such as body mass index, steroid use, and nutritional status, which may have differed between the study periods, were not measured \[[@CR2]\]. We also did not track information on the dosage of antimicrobials used in SAP or in additional antimicrobial administration for the longer operations. Lastly, as mentioned above, other modifiable measures (e.g. adequate skin preparation solutions, patient warming, and glycemic control) might have played an important role in preventing SSI.

Conclusions {#Sec10}
===========

Although preoperative SAP is important, the timing of preoperative SAP within the 60-min window may be a minor detail for laparoscopic surgery. Moreover, other modifiable measures should be incorporated into comprehensive surgical quality improvement initiatives to reduce SSI.

Appendix {#Sec11}
========

Appendix 1Recommended preoperative surgical antimicrobial prophylaxis at the study institutionType of procedureAgentsDoseRedosing interval, hourGastrectomycefazolin1--2 g3--4Cholecystectomycefazolin\
ampicillin/sulbactam1-2 g\
1.5-3 g3--4\
2--3Appendectomycefazolin + metronidazole\
cefmetazole\
ampicillin/sulbactam1-2 g + 500 mg\
1-2 g\
1.5-3 g3--4 + 8\
2--3\
2--3Colorectal surgerycefazolin + metronidazole\
cefmetazole\
ampicillin/sulbactam1-2 g + 500 mg\
1-2 g\
1.5-3 g3--4 + 8\
2--3\
2--3NOTE. For patients with β-lactam allergy and renal failure, infectious disease consultation is recommended

Appendix 2Univariate analysis of factors associated with development of SSIVariablesNo SSI *n* = 1207SSI *n* = 190*P* valueAge, median, (IQR) years66 (52--75)70 (60--77)0.001  \< 65, n (%)554 (45.9)71 (37.4)0.028  ≥ 65, n (%)653 (54.1)119 (62.6)Male gender, n (%)532 (44.1)74 (39.0)0.19Co-morbidities, n (%) Diabetes mellitus164 (13.6)28 (14.7)0.67 Chronic lung diseases57 (4.7)12 (6.3)0.35 Cardiovascular diseases59 (4.9)10 (5.3)0.83 Hypertension442 (36.6)71 (37.4)0.84 Dyslipidemia198 (16.4)33 (17.4)0.74Current smoker, n (%)560 (46.4)110 (47.9)0.003ASA score, n (%) 1 no disturbance250 (20.7)29 (15.3)Ref. 2 mild disturbance854 (70.8)144 (75.8)0.08 3 severe disturbance99 (8.2)17 (9.0)0.23 4 life-threatening4 (0.3)0 (0)N/AWound class, n (%) 2 clean-contaminated1202 (99.6)188 (99.0)0.25 3 contaminated5 (0.4)2 (1.1)0.25Emergent surgery, n (%)200 (16.6)22 (11.6)0.080Type of surgery, n (%) Cholecystectomy291 (24.1)16 (8.4)Ref. Gastrectomy294 (24.4)77 (40.5)\< 0.001 Appendectomy140 (11.6)17 (9.0)0.029 Colectomy175 (14.5)25 (13.2)0.004 Proctectomy306 (25.4)55 (29.0)\< 0.001 Cholecystectomy and appendectomy1 (0.1)0 (0)N/AOperation time, median, (IQR) min205 (131--285)273 (197--337)\< 0.001  \< 180, n (%)502 (41.6)42 (22.1)  ≥ 180, n (%)705 (58.4)148 (77.9)\< 0.001SAP drip infusion time, median, (IQR) min18 (14--23)18 (14--24)0.97Time from SAP completion to surgical incision, median, (IQR) min12 (4--25)15 (3--31)0.37 31--60 min175 (14.5)42 (22.2)Ref.  \< 0 min143 (11.9)23 (12.2)0.16 0--30 min861 (71.4)119 (63.0)0.005  \> 60 min26 (2.2)6 (3.2)0.52Intervention status, "yes"395 (32.7)60 (31.6)0.75NOTE. *SSI* surgical site infection, *IQR* interquartile range, *ASA* American Society of Anesthesiologists, *SAP* surgical antimicrobial prophylaxis, *N/A* not applicable

Appendix 3Subgroup analysis of different types of SSINo SSI\
(*n* = 1207)Superficial SSI\
(*n* = 113)Deep and organ space SSI\
(*n* = 77)*P* valueNo SSI vs superficial SSINo SSI vs deep and organ space SSIAge, median, (IQR) years66 (52--75)67 (53--76)72 (64--78)0.49\< 0.001 \< 65, n (%)554 (45.9)50 (44.3)21 (27.3)0.740.018 ≥ 65, n (%)653 (54.1)63 (55.7)56 (72.7)Male gender, n (%)532 (44.1)57 (50.4)17 (22.1)0.19\< 0.001Co-morbidities, n (%) Diabetes mellitus164 (13.6)13 (11.5)15 (19.5)0.530.15 Chronic lung diseases57 (4.7)6 (5.3)6 (7.8)0.780.23 Cardiovascular diseases59 (4.9)7 (6.2)3 (3.9)0.540.69 Hypertension442 (36.6)38 (33.6)33 (42.9)0.530.27 Dyslipidemia198 (16.4)19 (16.8)14 (18.2)0.910.68Current smoker, n (%)560 (46.4)58 (51.3)52 (67.5)0.32\< 0.001ASA score, n (%) 1 (no disturbance)250 (20.7)22 (19.5)7 (9.1)Ref.Ref. 2 (mild disturbance)854 (70.8)82 (72.6)62 (80.5)0.730.02 3 (severe disturbance)99 (8.2)9 (8.0)8 (10.4)0.940.05 4 (life-threatening)4 (0.3)0 (0)0 (0)N/AN/AWound class, n (%) 2 clean-contaminated1202 (99.6)112 (99.1)76 (98.7)0.480.27 3 contaminated5 (0.4)1 (0.9)1 (1.3)0.480.27Emergent surgery, n (%)200 (16.6)16 (14.2)6 (7.8)0.510.04Type of surgery, n (%) Cholecystectomy291 (24.1)11 (9.7)5 (6.5)Ref.Ref. Gastrectomy294 (24.4)28 (24.8)49 (63.6)0.011\< 0.001 Appendectomy140 (11.6)14 (12.4)3 (3.9)0.0190.77 Colectomy175 (14.5)16 (14.2)9 (11.7)0.0280.05 Proctectomy306 (25.4)44 (38.9)11 (14.3)\< 0.0010.18 Cholecystectomy and appendectomy1 (0.1)0 (0)0 (0)N/AN/AOperation time, median, (IQR) min205 (131--285)229 (164--296)325 (271--399)0.015\< 0.001  \< 180, n (%)502 (41.6)33 (29.2)9 (11.7)0.01\< 0.001  ≥ 180, n (%)705 (58.4)80 (70.8)68 (88.3)SAP drip infusion time, median, (IQR) min18 (14--23)18 (14--25)17 (13--22)0.520.46Time from SAP completion to surgical incision, median, (IQR) min12 (4--25)14 (2--31)17 (6--29)0.390.69Time windows, n (%) 31--60 min175 (14.5)24 (21.2)18 (23.4)Ref.Ref. \< 0 min143 (11.9)18 (15.9)5 (6.5)0.800.04 0--30 min861 (71.4)65 (57.5)54 (70.1)0.020.08 \> 60 min26 (2.2)6 (5.3)0 (0)0.30N/AIntervention status, "yes"395 (32.7)35 (31.0)25 (32.5)0.700.83NOTE. *SSI* surgical site infection, *IQR* interquartile range, *ASA* American Society of Anesthesiologists, *SAP* surgical antimicrobial prophylaxis, *N/A* not applicable

ASA

:   American Society of Anesthesiologists

CDC

:   Center for Disease Control and Prevention

SAP

:   Surgical antimicrobial prophylaxis

SSI

:   Surgical site infection

WHO

:   World Health Organization
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